1. Home
  2. Pharma & Healthcare
  3. Global and Japan Hormone Refractory Prostate Cancer (HRPCA) Market 2020 by Company, Type and Application, Forecast to 2025

Global and Japan Hormone Refractory Prostate Cancer (HRPCA) Market 2020 by Company, Type and Application, Forecast to 2025

Publication Month: Mar 2020 | No. of Pages: 91 Published By: Global Info Research
Single User License: US $ 3980
Corporate User License: US $ 7960

Market Overview
The global Hormone Refractory Prostate Cancer (HRPCA) market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 4.8% in the forecast period of 2020 to 2025 and will expected to reach USD 8649.2 million by 2025, from USD 7162.2 million in 2019.

The Hormone Refractory Prostate Cancer (HRPCA) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Hormone Refractory Prostate Cancer (HRPCA) market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for revenue by Type and Application. This analysis can help you expand your business by targeting qualified niche markets.

Breakdown by Type, Hormone Refractory Prostate Cancer (HRPCA) market has been segmented into Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, Surgery, etc.

Breakdown by Application, Hormone Refractory Prostate Cancer (HRPCA) has been segmented into Hospitals, Ambulatory Surgical Centers, Specialty Clinics, etc.

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Hormone Refractory Prostate Cancer (HRPCA) market presented in the report. This section sheds light on the sales growth of different regional and country-level Hormone Refractory Prostate Cancer (HRPCA) markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Hormone Refractory Prostate Cancer (HRPCA) market.

For Japan, this report analyses the Japan market by players, Type and Application, for the period 2015-2025.

Competitive Landscape and Hormone Refractory Prostate Cancer (HRPCA) Market Share Analysis
Hormone Refractory Prostate Cancer (HRPCA) competitive landscape provides details by vendors, including company overview, company total revenue, market potential, global presence, Hormone Refractory Prostate Cancer (HRPCA) revenue generated, market share, headquarters, SWOT analysis, product launch. For the period 2015-2020, this study provides the Hormone Refractory Prostate Cancer (HRPCA) revenue and market share for each player covered in this report.

The major players covered in Hormone Refractory Prostate Cancer (HRPCA) are: Astellas Inc, Johnson & Johnson, Sanofi S.A, Dendreon Corporation, Bayer AG, etc. Among other players domestic and global, Hormone Refractory Prostate Cancer (HRPCA) market share data is available for global, North America, Europe, Asia, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Market segment by players, this report covers
Astellas Inc
Johnson & Johnson
Sanofi S.A
Dendreon Corporation, Bayer AG

Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina)
MENA (Saudi Arabia, UAE, Turkey and South Africa)

Market segment by Type, covers:
Chemotherapy
Hormonal Therapy
Immunotherapy
Radiation Therapy
Surgery

Market segment by Application, can be divided into
Hospitals
Ambulatory Surgical Centers
Specialty Clinics

Table of Contents

1 Market Overview
1.1 Product Overview and Scope of Hormone Refractory Prostate Cancer (HRPCA)
1.2 Classification of Hormone Refractory Prostate Cancer (HRPCA) by Type
1.2.1 Overview: Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Type: 2015 Versus 2019 Versus 2025
1.2.2 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type in 2019
1.2.3 Chemotherapy
1.2.4 Hormonal Therapy
1.2.5 Immunotherapy
1.2.6 Radiation Therapy
1.2.7 Surgery
1.3 Global Hormone Refractory Prostate Cancer (HRPCA) Market by Application
1.3.1 Overview: Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Application: 2015 Versus 2019 Versus 2025
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Specialty Clinics
1.4 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2015-2025)
1.5 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Regions: 2015 VS 2019 VS 2025
1.6 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Regions (2015-2020)
1.7 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast by Regions (2020-2025)
1.7.1 North America Hormone Refractory Prostate Cancer (HRPCA) Status and Prospect (2015-2025)
1.7.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Status and Prospect (2015-2025)
1.7.3 Asia Hormone Refractory Prostate Cancer (HRPCA) Status and Prospect (2015-2025)
1.7.4 South America Hormone Refractory Prostate Cancer (HRPCA) Status and Prospect (2015-2025)
1.7.5 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Status and Prospect (2015-2025)

2 Company Profiles
2.1 Astellas Inc
2.1.1 Astellas Inc Details
2.1.2 Astellas Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Astellas Inc SWOT Analysis
2.1.4 Astellas Inc Product and Services
2.1.5 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Revenue, Gross Margin and Market Share (2018-2019)
2.2 Johnson & Johnson
2.2.1 Johnson & Johnson Details
2.2.2 Johnson & Johnson Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Johnson & Johnson SWOT Analysis
2.2.4 Johnson & Johnson Product and Services
2.2.5 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Revenue, Gross Margin and Market Share (2018-2019)
2.3 Sanofi S.A
2.3.1 Sanofi S.A Details
2.3.2 Sanofi S.A Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Sanofi S.A SWOT Analysis
2.3.4 Sanofi S.A Product and Services
2.3.5 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Revenue, Gross Margin and Market Share (2018-2019)
2.4 Dendreon Corporation, Bayer AG
2.4.1 Dendreon Corporation, Bayer AG Details
2.4.2 Dendreon Corporation, Bayer AG Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Dendreon Corporation, Bayer AG SWOT Analysis
2.4.4 Dendreon Corporation, Bayer AG Product and Services
2.4.5 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Revenue, Gross Margin and Market Share (2018-2019)

3 Market Competition, by Players
3.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Players (2015-2020)
3.2 Japan Hormone Refractory Prostate Cancer (HRPCA) Market Size by Players (2015-2020)
3.3 Market Concentration Rate
3.3.1 Top 5 Hormone Refractory Prostate Cancer (HRPCA) Players Market Share
3.3.2 Top 10 Hormone Refractory Prostate Cancer (HRPCA) Players Market Share

4 North America Market Size and Forecast by Countries
4.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Countries (2015-2020)
4.2 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast by Countries (2015-2026)
4.3 United States Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2015-2025)
4.4 Canada Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2015-2025)
4.5 Mexico Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2015-2025)

5 Europe Market Size and Forecast by Countries
5.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Countries (2015-2020)
5.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast by Countries (2015-2026)
5.3 Germany Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2015-2025)
5.4 France Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2015-2025)
5.5 UK Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2015-2025)
5.6 Russia Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2015-2025)
5.7 Italy Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2015-2025)

6 Asia-Pacific Market Size and Forecast by Countries
6.1 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Regions (2015-2020)
6.2 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast by Regions (2015-2026)
6.3 China Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2015-2025)
6.4 Japan Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2015-2025)
6.5 Korea Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2015-2025)
6.6 India Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2015-2025)
6.7 Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2015-2025)

7 South America Market Size and Forecast by Countries
7.1 South America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Countries (2015-2020)
7.2 South America Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast by Countries (2015-2026)
7.3 Brazil Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2015-2025)
7.4 Argentina Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2015-2025)

8 Middle East & Africa Market Size and Forecast by Countries
8.1 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue by Regions (2015-2020)
8.2 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast by Countries (2015-2026)
8.3 Saudi Arabia Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2015-2025)
8.4 UAE Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2015-2025)
8.5 Egypt Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2015-2025)
8.6 South Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast (2015-2025)

9 Market Size Segment by Type
9.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast by Type (2015-2025)
9.1.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2015-2020)
9.1.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Forecast by Type (2020-2025)
9.2 Japan Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast by Type (2015-2025)
9.2.1 Japan Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2015-2020)
9.2.2 Japan Hormone Refractory Prostate Cancer (HRPCA) Market Size Forecast by Type (2020-2025)

10 Market Size Segment by Application
10.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast by Application (2015-2025)
10.1.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2015-2020)
10.1.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Forecast by Application (2020-2025)
10.2 Japan Hormone Refractory Prostate Cancer (HRPCA) Market Size and Forecast by Application (2015-2025)
10.2.1 Japan Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2015-2020)
10.2.2 Japan Hormone Refractory Prostate Cancer (HRPCA) Market Size Forecast by Application (2020-2025)

11 Research Findings and Conclusion

12 Appendix
12.1 Methodology
12.2 Data Source
12.3 Disclaimer
12.4 About US

Tables and Figures

List of Tables

Table 1. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) by Type: 2015 Versus 2019 Versus 2025
Table 2. Breakdown of Hormone Refractory Prostate Cancer (HRPCA) by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) by Application: 2015 Versus 2019 Versus 2025
Table 4. Global Market Hormone Refractory Prostate Cancer (HRPCA) Market Size (USD Million) Comparison by Regions (2020-2025)
Table 5. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) by Regions (2015-2020)
Table 6. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Regions (2015-2020)
Table 7. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) by Regions (2020-2025)
Table 8. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Regions (2020-2025)
Table 9. Astellas Inc Corporate Information, Location and Competitors
Table 10. Astellas Inc Major Business
Table 11. Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Total Revenue (USD Million) (2017-2018)
Table 12. Astellas Inc SWOT Analysis
Table 13. Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Product and Solutions
Table 14. Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 15. Johnson & Johnson Corporate Information, Location and Competitors
Table 16. Johnson & Johnson Major Business
Table 17. Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Total Revenue (USD Million) (2018-2019)
Table 18. Johnson & Johnson SWOT Analysis
Table 19. Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Product and Solutions
Table 20. Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 21. Sanofi S.A Corporate Information, Location and Competitors
Table 22. Sanofi S.A Major Business
Table 23. Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Total Revenue (USD Million) (2017-2018)
Table 24. Sanofi S.A SWOT Analysis
Table 25. Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Product and Solutions
Table 26. Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 27. Dendreon Corporation, Bayer AG Corporate Information, Location and Competitors
Table 28. Dendreon Corporation, Bayer AG Major Business
Table 29. Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Total Revenue (USD Million) (2017-2018)
Table 30. Dendreon Corporation, Bayer AG SWOT Analysis
Table 31. Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Product and Solutions
Table 32. Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 33. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) by Players (2015-2020)
Table 34. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Players (2015-2020)
Table 35. Key Players Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) in Japan (2015-2020)
Table 36. Key Players Hormone Refractory Prostate Cancer (HRPCA) Revenue Share in Japan (2015-2020)
Table 37. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) by Countries (2015-2020)
Table 38. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries (2015-2020)
Table 39. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) by Countries (2020-2026)
Table 40. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries (2020-2026)
Table 41. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) by Countries (2015-2020)
Table 42. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries (2015-2020)
Table 43. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) by Countries (2020-2026)
Table 44. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries (2020-2026)
Table 45. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) by Countries (2015-2020)
Table 46. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries (2015-2020)
Table 47. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) by Countries (2020-2026)
Table 48. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries (2020-2026)
Table 49. South America Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) by Countries (2015-2020)
Table 50. South America Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries (2015-2020)
Table 51. South America Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) by Countries (2020-2026)
Table 52. South America Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries (2020-2026)
Table 53. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) by Countries (2015-2020)
Table 54. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries (2015-2020)
Table 55. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) by Countries (2020-2026)
Table 56. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Countries (2020-2026)
Table 57. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) by Type (2015-2020)
Table 58. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Type (2015-2020)
Table 59. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Forecast by Type (2020-2025)
Table 60. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share Forecast by Type (2020-2025)
Table 61. Japan Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) by Type (2015-2020)
Table 62. Japan Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Type (2015-2020)
Table 63. Japan Hormone Refractory Prostate Cancer (HRPCA) Revenue Forecast by Type (2020-2025)
Table 64. Japan Hormone Refractory Prostate Cancer (HRPCA) Market Share Forecast by Type (2020-2025)
Table 65. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) by Application (2015-2020)
Table 66. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Application (2015-2020)
Table 67. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Forecast by Application (2020-2025)
Table 68. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share Forecast by Application (2020-2025)
Table 69. Japan Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) by Application (2015-2020)
Table 70. Japan Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Application (2015-2020)
Table 71. Japan Hormone Refractory Prostate Cancer (HRPCA) Revenue Forecast by Application (2020-2025)
Table 72. Japan Hormone Refractory Prostate Cancer (HRPCA) Market Share Forecast by Application (2020-2025)
List of Figures
Figure 1. Hormone Refractory Prostate Cancer (HRPCA) Picture
Figure 2. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 3. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type in 2019
Figure 4. Chemotherapy Picture
Figure 5. Hormonal Therapy Picture
Figure 6. Immunotherapy Picture
Figure 7. Radiation Therapy Picture
Figure 8. Surgery Picture
Figure 9. Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Application in 2019
Figure 10. Hospitals Picture
Figure 11. Ambulatory Surgical Centers Picture
Figure 12. Specialty Clinics Picture
Figure 13. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue and Growth Rate (2015-2025) (USD Million)
Figure 14. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Share by Regions (2015-2025)
Figure 15. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Share by Regions in 2019
Figure 16. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Regions (2020-2025)
Figure 17. North America Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) and Growth Rate (2015-2025)
Figure 18. Europe Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) and Growth Rate (2015-2025)
Figure 19. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) and Growth Rate (2015-2025)
Figure 20. South America Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) and Growth Rate (2015-2025)
Figure 21. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Revenue (USD Million) and Growth Rate (2015-2025)
Figure 22. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Players in 2019
Figure 23. Global Top 5 Players Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share in 2019
Figure 24. Top 10 Players Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share in Global Market in 2019
Figure 25. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size (USD Million) by Type (2015-2025)
Figure 26. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Share by Application (2015-2025)
Figure 27. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size Share by Countries (2015-2025)
Figure 28. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size Share by Countries in 2019
Figure 29. United States Hormone Refractory Prostate Cancer (HRPCA) Market Size (USD Million) and Forecast (2015-2025)
Figure 30. Canada Hormone Refractory Prostate Cancer (HRPCA) Market Size (USD Million) and Forecast (2015-2025)
Figure 31. Mexico Hormone Refractory Prostate Cancer (HRPCA) Market Size (USD Million) and Forecast (2015-2025)
Figure 32. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size Share by Countries (2015-2025)
Figure 33. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size Share by Countries in 2019
Figure 34. Germany Hormone Refractory Prostate Cancer (HRPCA) Market Size (USD Million) and Forecast (2015-2025)
Figure 35. France Hormone Refractory Prostate Cancer (HRPCA) Market Size (USD Million) and Forecast (2015-2025)
Figure 36. Russia Hormone Refractory Prostate Cancer (HRPCA) Market Size (USD Million) and Forecast (2015-2025)
Figure 37. Italy Hormone Refractory Prostate Cancer (HRPCA) Market Size (USD Million) and Forecast (2015-2025)
Figure 38. Spain Hormone Refractory Prostate Cancer (HRPCA) Market Size (USD Million) and Forecast (2015-2025)
Figure 39. UK Hormone Refractory Prostate Cancer (HRPCA) Market Size (USD Million) and Forecast (2015-2025)
Figure 40. Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size Share by Countries (2015-2025)
Figure 41. Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size Share by Countries in 2019
Figure 42. China Hormone Refractory Prostate Cancer (HRPCA) Market Size (USD Million) and Forecast (2015-2025)
Figure 43. Japan Hormone Refractory Prostate Cancer (HRPCA) Market Size (USD Million) and Forecast (2015-2025)
Figure 44. Korea Hormone Refractory Prostate Cancer (HRPCA) Market Size (USD Million) and Forecast (2015-2025)
Figure 45. India Hormone Refractory Prostate Cancer (HRPCA) Market Size (USD Million) and Forecast (2015-2025)
Figure 46. Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size (USD Million) and Forecast (2015-2025)
Figure 47. South America Hormone Refractory Prostate Cancer (HRPCA) Market Size Share by Countries (2015-2025)
Figure 48. South America Hormone Refractory Prostate Cancer (HRPCA) Market Size Share by Countries in 2019
Figure 49. Brazil Hormone Refractory Prostate Cancer (HRPCA) Market Size (USD Million) and Forecast (2015-2025)
Figure 50. Argentina Hormone Refractory Prostate Cancer (HRPCA) Market Size (USD Million) and Forecast (2015-2025)
Figure 51. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size Share by Countries (2015-2025)
Figure 52. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size Share by Countries in 2019
Figure 53. Saudi Arabia Hormone Refractory Prostate Cancer (HRPCA) Market Size (USD Million) and Forecast (2015-2025)
Figure 54. UAE Hormone Refractory Prostate Cancer (HRPCA) Market Size (USD Million) and Forecast (2015-2025)
Figure 55. Egypt Hormone Refractory Prostate Cancer (HRPCA) Market Size (USD Million) and Forecast (2015-2025)
Figure 56. South Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size (USD Million) and Forecast (2015-2025)
Figure 57. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Type (2015-2020)
Figure 58. Japan Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Type (2015-2020)
Figure 59. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Application (2015-2020)
Figure 60. Japan Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Application (2015-2020)




Companies Mentioned
Astellas Inc
Johnson & Johnson
Sanofi S.A
Dendreon Corporation, Bayer AG

Reason to Buy

  • Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The segment that is expected to dominate the Pharma & Healthcare Market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets